Servier and Aqemia extend collaboration on non-drugable target in immuno-oncology

[ad_1]

PARIS, Jan. 9, 2023–(BUSINESS WIRE)–Servier and Aqemia announce the extension of their collaboration for the discovery of a new molecule on a drug-free therapeutic target in immuno-oncology.

This extension follows the successful partnership program of Servier and Aqemias, which began in December 2021, to accelerate the discovery of drug candidates in immuno-oncology using artificial intelligence.

“We are excited about this new step in our collaboration with Aqemia, which illustrates Servier’s development in the field of artificial intelligence and demonstrates our commitment to immuno-oncology,” said Olivier Nosjean, director of open innovation and Servier’s scientific affairs.

“We are thrilled to continue collaborating with the Servier teams. This extension shows a common willingness to pool our strengths and expertise to drug this extremely difficult target.” says Maximilien Levesque, CEO and co-founder of Aqemia.

Aqemia has successfully employed its unique quantum physics-inspired artificial intelligence technology to identify novel, patentable molecules that are experimentally active on a non-drugable target in immuno-oncology.

Unlike other AI technologies that require experimental results to train their algorithms for each new target and chemical series, Aqemia generates its data with quantum physics, allowing it to work on particularly innovative and non-drugable targets.

Pharmaceutical startup Aqemia will continue to use its algorithms to optimize molecules collaboratively found by both partners, relying on the launchpad platform that the startup has developed for its own research projects.

The new agreement provides for a new upfront payment as well as payments linked to the achievement of research and development milestones by drug candidates identified through the collaboration between Aqemia and Servier.

—

About Servier

Founded to serve health, Servier is a global pharmaceutical group governed by a Foundation that aspires to make a significant social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its calling with a long-term vision: to engage in therapeutic progress to meet patients’ needs. The 21,800 employees of the Group are committed to this common vocation, a source of inspiration every day.

The story continues

As a world leader in cardiology, Servier’s ambition is to become a renowned, focused and innovative player in oncology, targeting difficult-to-treat cancers. For this reason, the Group allocates more than 50% of its research and development budget to the development of targeted and innovative therapies in oncology.

Neuroscience and immuno-inflammatory diseases are the growth drivers of the future. In these areas, Servier is focused on a limited number of pathologies in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

To promote access to quality care for all at a lower cost, the Group also offers a range of quality generics covering the majority of pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.

In all these areas, the Group includes the patient’s voice at every stage of a drug’s life cycle.

Headquartered in France, Servier can count on a strong geographical presence in over 150 countries and achieved a turnover of 4.7 billion in 2021.

More information on the new Group website: servier.com

Follow us on social media: LinkedIn, Facebook, Twitter, Instagram

About Acemia

Aqemia is a next-generation pharmaceutical company generating one of the fastest growing drug discovery pipelines in the world. Our mission is to rapidly design innovative drug candidates for dozens of critical diseases. What sets us apart are our unique quantum mechanical and statistical algorithms that power a generative AI to design new drug candidates. The disruptive speed and accuracy of our technology platform allows us to scale drug discovery projects as technology projects.

For more information visit us at www.aqemia.com or follow us on LinkedIn.

View the source version at businesswire.com: https://www.businesswire.com/news/home/20230109005398/en/

Contacts

Press contact Sonia Marques: [email protected] I tel. +33 (0)1 55 72 40 21

[ad_2]